12:56 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

Syntrix's dual CXCR1/CXCR2 inhibitor for combos in oral, lung cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; solid tumors Mouse studies suggest combining the dual CXCR1/CXCR2 inhibitor SX-682 with anti-PD-1 mAbs or T cell therapies could help treat oral and lung cancers. In mouse models of...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
07:00 , Jun 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Chemokine CXC motif ligand 1 (CXCL1; GRO; MGSA); CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB)

Cancer INDICATION: Prostate cancer Patient sample and mouse studies suggest inhibiting CXCL1- CXCR1 / CXCR2 signaling could help treat prostate cancer in obese patients. CXCL1 was highly expressed in tumor samples from 19 of 21...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CXC chemokine receptor 2 (CXCR2; IL8RB); programmed cell death 1 (PD-1; PDCD1; CD279)

Cancer INDICATION: Pancreatic cancer Patient sample and mouse studies suggest inhibiting CXCR2 could help treat pancreatic ductal adenocarcinoma (PDAC). In patient samples, high levels of CXCR2 in neutrophils at the tumor borders correlated with disease...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Reparixin: Phase II started

Dompe began a double-blind, placebo-controlled, international Phase II trial to compare 1,200 mg oral reparixin thrice daily for the first 21 days of a 28-day cycle plus IV paclitaxel on days 1, 8 and 15...
08:00 , Dec 4, 2014 |  BC Innovations  |  Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations...
07:00 , Oct 30, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation CXC chemokine receptor 1 (CXCR1); CXCR2 (IL8RB) In vitro and mouse studies suggest a new class of dual CXCR1 and CXCR2 inhibitors could help...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Tuberculosis Chemokine CXC motif ligand 5 (CXCL5; ENA78); CXC chemokine receptor 2 (CXCR2; IL8RB) Mouse studies suggest inhibiting the CXCL5-CXCR2...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Dompe, SatRx LLC deal

Dompe and SatRx partnered to develop and commercialize Dompe's Reparixin in Russia to improve liver transplantation outcomes. Clinical studies will be co-financed by the parties, and Dompe said development activities and strategies will be governed...